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The development of antibiotics has been marked as one of the
greatest medical advances of the past century; their use has saved
millions of lives, increased life expectancies, and led to a number of
other important medical advances.1 However, the effectiveness of
antibiotics has become seriously threatened due to massive overuse
and improper dosing, and as a result, antibiotic resistant bacteria
have become one of the greatest threats to human health world-
wide.2 Yet, even though antibiotic resistance is widely recognized
as an impending public health crisis, approximately 24.6 million
pounds of antibiotics, roughly 70% of all antibiotics produced, are
consumed by the meat industry each year.3 Despite decades of sci-
entific research showing adverse human health consequences asso-
ciated with antibiotic use in food animals and numerous pleas for
binding regulations, the federal government has refused to man-
date a reduction in the enormous amounts of antibiotics used in an-
imal production.4
This article starts by providing background information on anti-
biotic resistance. It then explores the actions taken by the Food and
Drug Administration ("FDA") regarding the use of medically im-
portant antibiotics,5 traces the Second Circuit decision in National
Resources Defense Council, Inc. v. U.S. Food and Drug Administra-
tion ("NRDC III')6, which upheld the FDA's actions, and presents
1. PRESIDENT'S COUNCIL OF ADVISORS ON SCI. AND TECH., EXEC. OFFICE OF THE
PRESIDENT, REP. TO THE PRESIDENT ON COMBATING ANTIBIOTIC RESISTANCE, at 1 (2014)
[hereinafter PCAST REPORT].
2. U.S. DEP'T OF HEALTH & HUMAN SERV, CTR. FOR DISEASE CONTROL AND PREVENTION,
ANTIBIOTIC RESISTANCE THREATS IN THE UNITED STATES, at 11 (2013) [hereinafter CDC
REPORT]. Eradicating the world's ability to fight routine infectious diseases such as pneu-
monia, meningitis, sore throat, general skin, bone and blood infections, foodborne illnesses,
and many more, will result in higher death tolls from primary infections and unperformed
procedures predicated on disease treatment. INTERAGENCY TASK FORCE ON ANTIMICROBIAL
RESISTANCE (ITFAR), A PUBLIC HEALTH ACTION PLAN TO COMBAT ANTIMICROBIAL
RESISTANCE, at 5 (2012) [hereinafter ITFAR REPORT].
3. MARGARET MELLON, CHARLES BENBROOK, AND KAREN LUTZ BENBROOK, HOGGING IT:
ESTIMATES OF ANTIMICROBIAL ABUSE IN LIVESTOCK, at xi (Union of Concerned Scientists ed.
2001).
4. See generally THE PEW CHARITABLE TRUSTS, ANTIBIOTIC RESISTANCE AND FOOD
ANIMAL PRODUCTION: A BIBLIOGRAPHY OF SCIENTIFIC STUDIES (1969-2014) (Antibiotic Re-
sistance Project ed., 2013).
5. The term "medically important antimicrobial drugs" generally refers to antimicrobial
drugs that are important for therapeutic use in humans. FOOD AND DRUG ADMIN., CTR. FOR
VETERINARY MED., GUIDANCE FOR INDUSTRY #209: THE JUDICIOUS USE OF MEDICALLY
IMPORTANT ANTIMICROBIAL DRUGS IN FOOD-PRODUCING ANIMALS, 3, n. 1 (2012) [hereinafter
GFI #209].
6. 760 F.3d 151 (2d Cir. 2014) [hereinafter "NRDC II"]
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the proposed actions taken by Congress and the Obama Admin-
istration in the past decade. Finally, the article makes several pro-
posals for the future based on the successes of other countries in
removing the non-judicious use of antibiotics in food-producing an-
imals.7 While this article focuses on a critique of the government's
actions to date, it ultimately aims to highlight that non-judicious
antibiotic use in food animals can and should be stopped in order to
help preserve the effectiveness of one of the greatest advances in
modern medicine.
II. BACKGROUND
A. The Threat of Antibiotic Resistance
The discovery of antibiotics as a means to combat bacterial infec-
tion was accompanied by the discovery that antibiotic use would
also lead to increased bacterial resistance.8 In a simplified expla-
nation, when an antibiotic is insufficient to kill off all of the bacteria
in an organism, the surviving bacteria multiply and pass resistance
traits to new bacteria through inheritance.9 Resistance traits can
be combined through inheritance, creating new strains of bacteria
that are resistant to a number of the antibiotics designed to treat
them.10
Bacteria that are resistant to one or more classes of antibiotics
have become increasingly common." In fact, a number of bacterial
7. Carol Cogliani, Herman Goossens, & Christina Greko, Restricting Antimicrobial Use
in Food Animals: Lessons from Europe. 6 MICROBE 274 (2011).
8. Richard A. Stein, Antibiotic Resistance: A Global, Interdisciplinary Concern, 73 THE
AMERICAN BIOLOGY TEACHER 314, 317 (2011).
9. U.S. Gov'T ACCOUNTABILITY OFF., GAO-04-490, REPORT TO CONGRESSIONAL
REQUESTERS, ANTIBIOTIC RESISTANCE: FEDERAL AGENCIES NEED TO BETTER FOCUS EFFORTS
TO ADDRESS RISK TO HUMANS FROM ANTIBIOTIC USE IN ANIMALS 9 (2004) [hereinafter GAO
REPORT ON ANTIBIOTIC RESISTANCE]. The problem of drug resistance is particularly threat-
ening because of both the speed in which bacteria propagate and because bacterial transfer-
ence between species can occur. Robyn L. Goforth & Carol R. Goforth, Appropriate Regula-
tion of Antibiotics in Livestock Feed, 28 B.C. ENVTL. AFF. L. REV. 39, 44-45 (2000).
10. See Charles W. Schmidt, Antibiotic Resistance in Livestock: More at Stake than Steak,
110 ENVTL. HEALTH PERSP., A396, A400 (2002); Stein, supra note 8, at 315. Bacterial strains
that are resistant to multiple antibiotics are commonly known as superbugs. Id.
11. CDC REPORT, supra note 2, at 5. In the U.S. alone, at least 2 million people each
year acquire bacterial infections that are resistant to one or more of the antibiotics designed
to treat the infection. Id. at 11.
Examples of clinically important microbes that are rapidly developing resistance to
available antimicrobials include bacteria that cause pneumonia, ear infections, and
meningitis [...], skin, bone, lung, and bloodstream infections [...], urinary tract infec-
tions (e.g., Escherichia coli), foodborne infections (e.g., Salmonella or E. coli acquired
from meat, eggs, nuts, fresh produce etc.), and infections transmitted in healthcare
settings [...].
ITFAR REPORT, supra note 2, at 5.
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diseases are now almost entirely untreatable because the bacteria
have acquired resistance to all of the antibiotics that have been
used to combat them.12 Consequently, thousands of people die each
year either directly from antibiotic-resistant bacteria or indirectly
from other conditions complicated by antibiotic resistant infec-
tions.13 The growth of antibiotic-resistant bacteria also demands
extensive economic expenditures, both directly in the form of "pro-
longed and/or costlier treatments, extend[ed] hospital stays, [and]
additional doctor visits and healthcare use," as well as indirectly in
the form of lost productivity.14
In an attempt to preserve antibiotic effectiveness in light of the
severity of the problem, both national and international public
health and animal health organizations have developed judicious-
use guidelines that encourage selective use of antibiotics only for
necessary treatment and use with doctor/veterinary oversight.15
However, despite these recommendations and knowledge of the con-
sequences of overuse, antibiotics are still being misused at least
50% of the time.16 Thus, while antimicrobial resistance is not a new
phenomenon, the current magnitude of the problem has elevated
the issue of antibiotic resistance to a global crisis.17
Dr. Rima F. Khabbaz, Deputy Director of Infectious Diseases and
Director of the Office of Infectious Diseases at the Center for Dis-
ease Control ("CDC"), summarized the potential costs of antibiotic-
resistance in a 2014 symposium, stating that:
The cost of inaction is huge and unimaginable. It almost kind of
sounds like a doomsday scenario, but it is real. People talk about
returning to a pre-antibiotic era where simple infections, say a cut
12. PCAST REPORT, supra note 1, at 2. See Lena H. Sun and Brady Dennis, The super-
bug that doctors have been dreading just reached the U.S. THE WASHINGTON POST (May 27,
2016).
13. CDC REPORT, supra note 2, at 11; The Richard & Hinda Rosenthal Symposium 2014:
Antimicrobial Resistance: A Problem without Borders. Washington, DC: The National Acad-
emies Press (2014) [hereinafter IOM Symposium on Antimicrobial Resistance], at 6-7.
14. CDC REPORT, supra note 2, at 11. The CDC has estimated $20 billion in healthcare
costs can be directly attributed to antibiotic-resistant infections, and estimates of the indirect
costs to society-such as lost productivity-exceed $35 billion per year (measured in 2008).
Id. The CDC also estimates the annual impact of antibiotic-resistant infections to result in
8 million additional days in hospitals. PCAST REPORT, supra note 1, at 2.
15. GAO REPORT ON ANTIBIOTIC RESISTANCE, supra note 9, at 14.
16. See CDC REPORT, supra note 2, at 41; Nancy E. Halpern, Antibiotics in Food Animals:
The Convergence of Animal and Public Health, Science, Policy, Politics and the Law, 14
DRAKE J. AGRIC. L. 401, 407 (2009). In 1978, the WHO issued warnings about the impending
global resistance of pathogens, "blaming the problem on 'the widespread and indiscriminate
use of antimicrobial drugs in man and animals."' Id. (internal citation omitted).
17. PCAST REPORT, supra note 1, at 1; ITFAR REPORT, supra note 2, at 5.
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of a finger, cannot be treated. That is real. We have some patho-
gens where we no longer have any antibiotic that fights them.18
Finally, it is worth noting that the cost of inaction burdens the
global population, as drug resistant pathogens affect all people re-
gardless of age, gender, ethnicity, geographic border, or socioeco-
nomic background.19
B. Antibiotic Use in Farm Animals
The widespread use and misuse of antibiotics in human medicine
may be the principal connection between antibiotic resistance and
human disease; however, the use of antibiotics in animal production
has been shown to contribute to antibiotic resistance in humans for
over four decades.20 Scientists have found that resistant bacteria
bred in animals can be transferred to humans directly through in-
gestion of contaminated food products, directly through contact
with animals or livestock, and indirectly when antibiotic resistant
bacteria is released into the air, soil, or water-often occurring with
the spreading of manure.21 While there is still some debate as to
the degree of correlation between antibiotic use in animals and hu-
man antibiotic resistance,22 the scientific consensus is that antibi-
18. IOM Symposium on Antimicrobial Resistance, supra note 13, at 6. Scholars have
noted that "incrementally tweaking what we are doing is not going to get the job done." Id.
at 15.
19. ITFAR REPORT, supra note 2, at 5.
20. GAO REPORT ON ANTIBIOTIC RESISTANCE, supra note 9, at 1; Goforth & Goforth, su-
pra note 9, at 49. In 1969, the report of the Joint Committee, commissioned by the English
Parliament to study the use of antibiotics in animal husbandry and veterinary medicine, and
commonly known as the Swann Report, concluded that: "the administration of antibiotics to
farm livestock, particularly at sub-therapeutic levels, poses certain hazards to human and
animal health." Id. (internal citation omitted). The final recommendation was that only
antibiotics that are not used in human medicine should be used for growth promotion. Go-
forth & Goforth, supra note 9, at 49.
21. David C. Love, Meghan F. Davis, Anna Bassett, Andrew Gunther & Keeve E.
Nachman, Dose Imprecision and Resistance: Free-Choice Medicated Feeds in Industrial Food
Animal Production in the United States, 119 ENVTL. HEALTH PERSPS. 279, 280 (2011); Ariele
Lessing, Note, Killing Us Softly: How Sub-Therapeutic Dosing of Livestock Causes Drug-Re-
sistant Bacteria in Humans, 37 B.C. ENVTL. AFF. L. REV. 463, 474-75 (2010); LEO HORRIGAN,
JAY GRAHAM & SHAWN MCKENZIE, Antibiotic Drug Abuse, THE CAFO READER: THE TRAGEDY
OF INDUSTRIAL ANIMAL FACTORIES, 259 (ed. Daniel Imhoff) (2010).
22. While still acknowledging that transference is possible, there is a small number of
researchers that maintain that the health risks of the transference are minimal, or that more
research is needed to understand the degree of transfer. GAO REPORT ON ANTIBIOTIC
RESISTANCE, supra note 9, at 6. These researchers note that restricting the use of antibiotics
in meat could increase levels of infectious bacteria, potentially harming human health. See
e.g. I. Phillips, M. Casewell, T. Cox, B. De Groot, C. Friis, R. Jones, C. Nightingale, R. Preston
& J. Waddell, Does the Use of Antibiotics in Food Animals Pose a Risk to Human Health? A
Critical Review of Published Data, 53(1) J. ANTIMICROBIAL CHEMOTHERAPY, 28 (2004). No-
tably, this is the sole article cited by the GAO Report, and was written by an advisory group
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otic use in animals reduces the efficacy of the human antibiotic ar-
senal.23 In light of such evidence, over 350 expert organizations,
including the American Public Health Association and the World
Health Organization, have called for a ban on the nontherapeutic
use of antibiotics in food-producing animals.24
Shockingly, the quantities of antibiotics sold for use in food-pro-
ducing animals still dwarfs the amount used in human medicine;
for every one pound of antibiotic used in human medicine, eight
pounds are used for nontherapeutic purposes in livestock produc-
tion.25 Moreover, the list of antibiotics approved for use in animals
includes a number of drugs that are either used themselves for hu-
man patients or are closely related to such human drugs.26
The real problem is that almost all of the antibiotics used in live-
stock production are used in healthy animals for growth purposes
or disease prevention.27 To be sure, public health advocates do not
object to treating sick animals with antibiotics, but they do not want
to diminish the efficacy of these important drugs by feeding antibi-
otics to healthy animals.28 Further compounding the problem,
to the Animal Health Institute. GAO REPORT ON ANTIBIOTIC RESISTANCE, supra note 9, at
89.
23. Mellon, Benbrook, & Benbrook, supra note 3, at 1. In 2014, The PEW Charitable
Trusts complied a bibliography of the latest scientific studies and economic literature regard-
ing "the contribution of routine antibiotic use in food animals to the growing public health
crisis of human antibiotic resistance." THE PEW CHARITABLE TRUSTS, supra note 4, at 1. The
report concluded that current research supports the 2009 conclusion made by Dr. Frederick
J. Angulo, then acting associate director of science in the CDC's National Center for Envi-
ronmental Health and the Agency for Toxic Substances and Disease: "[t]here is scientific
consensus that antibiotic use in food animals contributes to resistance in humans. And
there's increasing evidence that such resistance results in adverse human health conse-
quences at the population level. Antibiotics are a finite and precious resource, and we need
to promote prudent and judicious antibiotic use." Id.
24. Lynn M. Boris, Note, The Food-Borne Ultimatum: Proposing Federal Legislation to
Create Human Living Conditions for Animals Raised for Food in Order to Improve Human
Health, 24 J.L. & HEALTH 285, 291 (2011); HORRIGAN ET AL., supra note 21, at 260.
25. Terence J. Centner, Regulating the Use of Non-Therapeutic Antibiotics in Food Ani-
mals, 21 GEO. INT'L ENVTL. L. REV. 1, 1 (2008).
26. Goforth & Goforth, supra note 9, at 47. The list includes: amoxicillin, ampicillin,
erythromycin, neomycin, penicillin, and tetracycline. Id. at 48; see also Carmen Cordova &
Avinash Kar, NRDC Issue Brief, Playing Chicken with Antibiotics: Previously Undisclosed
FDA Documents Show Antibiotic Feed Additives Don't meet the Agency's Own Safety Stand-
ards, 4 (Jan. 2014).
27. Mellon, Benbrook & Benbrook, supra note 3, at xii-xx; Centner, supra note 25, at 11.
Growth promotion relies on the idea that feeding animals low levels of antibiotics reduces
immune system activity, which would otherwise be tasked with combatting bad living condi-
tions, to free more resources for growth and weight gain. Boris, supra note 24, at 291. Dis-
ease prevention relies on the idea that antibiotics can be applied preventatively to combat
conditions associated with confined animal feeding operations or CAFOs. Id. at 291-92; see
Barbara O'Brien, Animal Welfare Reform and the Magic Bullet: The Use and Abuse of Sub-
therapeutic Doses of Antibiotics in Livestock, 67 U. COLO. L. REV. 407, 415 (1996).
28. Michael Pollan, Power Steer, THE NEW YORK TIMES MAGAZINE, Mar. 31, 2002. It is
worth noting that it currently remains unclear how much of an increase in meat production,
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growth promotion and disease prevention rely on a form of preemp-
tive application of antibiotics to healthy animals known as subther-
apeutic dosing.2 9 This involves the administration of low levels of
antibiotics, "insufficient to kill an invading bacterial infection, but
. . . effective in preventing bacterial infection from occurring."30
Subtherapeutic doses of antibiotics, prescribed over long periods of
time and which are not directed against a particular organism,31
create reservoirs of antibiotic-resistant bacteria that can lead to
new resistance traits and strains.32
Dr. Spellberg summarized the principal point this article aims to
make during the Institute of Medicine's Richard & Hinda Rosenthal
Symposium in 2014:
[Regarding] antibiotics in animal feed[,] [t]his is a national dis-
grace. There is no scientific debate here . . . It needs to end....
More challenging to think about, scientifically, is how we prevent
inappropriate antibiotic prescriptions among people.33
III. AGENCY ACTION
A. The FDA and the Federal Food, Drug, and Cosmetic Act
The FDA was established to protect against impure and unsafe
foods, drugs, cosmetics, and other potential hazards.34 Accordingly,
under the Federal Food, Drug, and Cosmetic Act ("FDCA"), the FDA
has been charged with regulating antibiotic use in animals used for
if any, actually results from routine use of in-feed additives. Stein, supra note 8, at 317.
Recent studies have shown remarkably modest weight gains and other benefits, indicating
that growth-promoting antibiotics offer very limited benefits. Peter Collignon, Henrik C.
Wegener, Peter Braam & Colin D. Butler, The Routine Use of Antibiotics to Promote Animal
Growth Does Little to Benefit Protein Undernutrition in the Developing World, 41 CLINICAL
INFECTIOUS DISEASES 1007, 1008-09 (2005). For example, a 2007 analysis of a study con-
ducted by Perdue Farms concluded that the benefits of antibiotic use were too small to cover
the cost of the drugs. Meghan F. Davis & Lainie Rutkow, Regulatory Strategies to Combat
Antimicrobial Resistance of Animal Origin: Recommendations for a Science-Based U.S. Ap-
proach, 25 TUL. ENVTL. L.J. 327, 362 (2012). Additionally, the amount of antibiotics needed
to promote growth has increased significantly over time, now requiring roughly ten to twenty
times the amount used four decades ago. Goforth & Goforth, supra note 9, at 46-47.
29. Lessing, supra note 21, at 469.
30. Id.; see also Love et. al., supra note 21, at 280.
31. See Lauren Orrico, Note, Squashing the Superbugs: A Proposed Multifaceted Ap-
proach to Combating Antibiotic-Resistant Bacteria, 27 J.L. & HEALTH 259, 264 (2014). For
example, drugs used for growth promotion or disease prevention are often administered to
food animals in the form of free-choice medicated feeds (FCMF), where each animal chooses
how much feed to consume. Love et. al, supra note 21, at 280. FCMF often results in the
inability to deliver predictable, uniform, or intended dose levels. Id.
32. GAO REPORT ON ANTIBIOTIC RESISTANCE, supra note 9, at 2; Love et. al., supra note
21, at 279.
33. IOM Symposium on Antimicrobial Resistance, supra note 13, at 15.
34. 21 U.S.C. § 393(a)-(b) (2012).
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food production.35 Under the FDCA, the FDA must review scientific
documentation on the safety and efficacy of a drug's proposed use
and approve its label before drug companies can market a new ani-
mal drug.36 The FDA considers an antimicrobial drug to be "safe"
if the agency concludes there is a "reasonable certainty of no harm
to human health from the proposed use of the drug in animals."37
In considering the safety of a drug, the FDA considers both the di-
rect toxic effects of the drug as well as indirect effects of the drug
on human health, including the potential human health impact of
antibiotic resistance stemming from the use of the drug in food-pro-
ducing animals.38
If safety issues arise after a drug's initial approval, the FDCA
provides grounds for withdrawal of approval.39 Section 360b(e)(1)
of the FDCA states, "the Secretary shall, after due notice and op-
portunity for hearing to the applicant, issue an order withdrawing
approval of an application ... if the Secretary finds-that experience
or scientific data show that such drug is unsafe for use."40 Under
this provision, the FDA has the initial burden to produce evidence
indicating that there are serious questions about he ultimate
safety of the drug used in food-producing animals. If the agency
meets this burden, the burden shifts to the sponsor to demonstrate
the safety of the drug.41
B. The Emergence and Reaffirmation of Safety Concerns
In the mid- 1960s, the FDA first became concerned that long-term
use of antibiotics in food animals could pose a serious threat to hu-
man and animal health.42 As early as 1970, a special task force,
created in response to those concerns, reported that the subthera-
peutic use of antibiotics in animal feed favors the development of
35. 21 U.S.C. § 360 (2012).
36. 21 U.S.C. § 360(a)(1) (2012). This is known as the New Animal Drug Approval pro-
cess (NADA).
37. GAO REPORT ON ANTIBIOTIC RESISTANCE, supra note 9, at 15.
38. Davis & Rutkow, supra note 28, at 355.
39. 21 U.S.C. § 360b(e).
40. 21 U.S.C. § 360b(e)(1) (emphasis added).
41. Davis & Rutkow, supra note 28, at 355. Notably, this burden shifting is in contrast
to regulatory efforts in other industries in which the burden of proof to demonstrate safety
remains with the producer at every stage, i.e. chemical production which is "similar in that
most antimicrobials are chemical compounds." Id.
42. See Nat. Res. Def. Council, Inc., v. U.S. Food and Drug Admin., 884 F. Supp. 2d 127,
132 (S.D.N.Y. 2012) [hereinafter NRDC I].
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antibiotic-resistant bacteria, and recommended restrictions on an-
tibiotic use in animal feed unless certain safety criteria were met.4 3
In light of the task force's findings, the FDA issued a regulation
stating that the agency proposed to withdraw approval of all sub-
therapeutic uses of antibiotics in animal feed, in accordance with
Section 360b(e)(1) of the FDCA, unless interested parties could pro-
vide evidence that the drugs met particular safety criteria set by
the FDA. 4 4
In reviewing data provided by the drug sponsors, the Director of
the Bureau of Veterinary Medicine ("BVM") 45 found that the data
failed to rebut findings indicating that the subtherapeutic use of
antibiotics was leading to an increase in antibiotic-resistant bacte-
ria, or that such resistant bacteria was being transferred from ani-
mals to humans. Subsequently, the Director of the BVM proposed
to withdraw approval of the use of penicillin and tetracyclines in
animal feed on the grounds "that the[se] drug products are not
shown to be safe," because the specified human and animal health
safety criteria had not been satisfied.4 6 As part of the withdrawal
process, the BVM then issued notices for an opportunity for hearing
("NOOHs") on proposals to withdraw approval of all subtherapeutic
uses of certain antibiotics in animal feed.47 Several drug sponsors
and agricultural organizations objected to the withdrawal of these
drugs, and the Commissioner of the FDA granted requests for hear-
ings regarding withdrawal. At the requested hearing, the drug
sponsors would have had the burden of proving that the drugs were
safe.4 8 If the drugs were in fact shown to be safe at the proposed
hearings, the FDA would rescind the proposals for withdrawal and
the drugs could continue to be used.
In the years between the FDA's grant of a hearing and its formal
action regarding the NOOHs, the agency repeatedly affirmed both
that certain antibiotic use in food-animals could be dangerous to
43. Id. The multi-agency task force consisted of scientists from the National Institute of
Health, the U.S. Department of Agriculture, the CDC, universities, and the agricultural and
pharmaceutical industries. Id.
44. Id. at 133. Some of the safety criteria included that subtherapeutic use of the drug
would not increase salmonella in animals, increase the pathogenicity of bacteria, or increase
the numbers of pathogenic bacteria or the resistance of pathogens to antibiotics used in hu-
man medicine. Id.
45. The Bureau of Veterinary Medicine is the subdivision of the FDA charged with re-
viewing animal drug applications and withdrawals. Id.
46. Id. at 134.
47. NRDCI, 884 F. Supp. 2d at 134.
48. Id. (citing FDA, Final Decision of the Commissioner, Withdrawal of Approval of the
New Animal Drug Application for Enrofloxacin in Poultry, 70 Fed. Reg. 44105).
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human health and that the issue of antibiotic resistance is of seri-
ous concern. For example, in 1983, the Commissioner of the FDA
explicitly denied requests from several drug sponsors to rescind the
NOOHs, explaining that the NOOHs "represent he Director's [and
Commission's] formal position that use of the drugs is not shown to
be safe."4 9 In 1996, the FDA and other health agencies collaborated
to form the National Antimicrobial Resistance Monitoring System
("NARMS") to monitor bacteria susceptibility.50 In 1999, the FDA
joined the Interagency Task Force on Antimicrobial Resistance
("ITFAR"), in an attempt to unify strategies regarding antimicro-
bial resistance.5 1 ITFAR recommendations have consistently sug-
gested that agencies must increase regulatory action regarding an-
timicrobial use in food-producing animals.52 In 2003, the FDA re-
leased Guidance Document #152 ("GFI 152"), setting guidelines for
new drug approval and again reaffirming its belief that antibiotic
use in animals has safety consequences for human health.5 3
C. FDA Action in Response to Findings
Ultimately, the hearings granted by the FDA in 1978 were never
held.54 Further, despite decades of data indicating the dangers of
subtherapeutic use of antibiotics in livestock, the FDA formally re-
scinded the 1977 NOOHs for the withdrawal of approval certain an-
tibiotics in animal feed on December 16, 2011.55 At that time, the
FDA also denied citizen suits from 1999 and 2005 that were filed
under Section 512(e) of the FDCA seeking to withdraw regulatory
approval for the subtherapeutic use of certain antibiotics in animal
feed, which were also based on the agency findings that led to the
1977 NOOHs.56
49. Id. at 135.
50. HHS, The National Antimicrobial Resistance Monitoring System (NARMS) Strategic
Plan, 2 (2012-16)
51. ITFAR REPORT, supra note 2, at 3-4. The Task Force is co-chaired by the Centers
for Disease Control and Prevention (CDC); Food and Drug Administration (FDA); and Na-
tional Institutes of Health (NIH). Id. at 3.
52. See ITFAR REPORT, supra note 2, at 3-4.
53. FOOD AND DRUG ADMIN., CTR. FOR VETERINARY MEDICINE, GUIDANCE FOR INDUSTRY
#152: EVALUATING THE SAFETY OF ANTIMICROBIAL NEW ANIMAL DRUGS WITH REGARD TO
THEIR MICROBIOLOGICAL EFFECTS ON BACTERIA OF HUMAN HEALTH CONCERN, 2 (2003)
[herein after GFI #152].
54. NRDCI, 884 F. Supp. 2d at 131.
55. Id. at 136; Withdrawal of Notices of Opportunity for a Hearing; Penicillin and Tetra-
cycline Used in Animal Feed, 76 Fed. Reg. 79,697 (Dec. 22, 2011).
56. Section 512(e) of the FDCA has been previously referred to in this article as Section
360b(e)(1) of the FDCA. Nat. Res. Def. Council, Inc., v. U.S. Food and Drug Admin., 872 F.
Supp. 2d 318, 324-27 (S.D.N.Y. 2012) [hereinafter NRDC II]. The list included penicillin and
tetracyclines, similarly subject to the 1977 NOOHs. Id. See Letter from Leslie Kux, Acting
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Although the FDA maintained that the drugs had not yet been
proven safe, the agency reasoned that they were implementing al-
ternative strategies for combating the negative effects of subthera-
peutic use of antibiotics in animal feed that would be more effi-
cient.5 7 However, the alternative strategies being pursued by the
FDA are the issuance of two guidance documents that carry no ac-
tual legal authority.5 8 In April 2013, the FDA issued Guidance Doc-
ument #209-The Judicious Use of Medically Important Antimicro-
bial Drugs in Food-Producing Animals ("GFI #209")-to encourage
judicious use of all medically important antimicrobial drugs.59 The
framework produced two principles: Medically important antibiot-
ics should be limited to uses considered necessary for assuring
health in food-producing animals, and, in the event that such use is
necessary, it should be limited to that which includes veterinary
oversight or consultation.60 The FDA formally stated in GFI #209,
"[i]n light of the risk that antimicrobial resistance poses to public
health, [the] FDA believes the use of medically important antimi-
crobial drugs in food-producing animals for production purposes
(e.g., to promote growth or improve feed efficiency) represents an
injudicious use of these important drugs."61 In December 2013, the
FDA followed with Guidance Document #213 ("GFI #213").62 GFI
#213 was intended to provide recommendations, information and
Assistant Commissioner for Policy, Food and Drug Administration, to Ms. Sarah Klein, Esq.,
Food Safety Program, Center for Science in the Public Interest (Nov. 7, 2011) (issuing the
final response from the FDA to the 1999 citizen petition) (hereinafter FDA denial of 1999
Citizen Petition); Letter from Leslie Kux, Acting Assistant Commissioner for Policy, Food
and Drug Administration, to Andrew Macquire, Vice President, Environmental Health, En-
vironmental Defense (Nov. 7, 2011) (issuing the final response from the FDA to the 2005
Citizen Petition) [hereinafter FDA denial of 2005 Citizen Petition].
57. NRDC 1, 884 F. Supp. 2d at 136.
58. See NRDC III., 760 F.3d 151, 176 (2d Cir. 2014) (Katzmann, CJ., dissenting).
59. GFI #209, supra note 5, at 21-22. In GFI #209, the FDA cited a non-exhaustive
summary of the scientific literature addressing questions regarding the use of antimicrobial
drugs in food-producing animals. Each of the studies stated, in one form or another, that
there is strong evidence of adverse human health consequences due to antibiotic-resistant
bacteria resulting from the use of antibiotics in food animals. Virtually of the studies listed
recommended that the U.S. ban the use of antimicrobials in growth promotion in animals if
those classes of drugs are also used in humans. Id. at 5-17.
60. Id. at 21-22.
61. Id. at 21. In regards to the use of antimicrobial drugs for disease prevention pur-
poses, the FDA deems it sometimes necessary and judicious as long as such use includes
professional veterinary involvement. The Administration "believes it is important to phase-
in the voluntary practice of including veterinary oversight or consultation in the use of these
drugs." Id. at 22.
62. . FOOD AND DRUG ADMIN., CTR. FOR VETERINARY MEDICINE, GUIDANCE FOR
INDUSTRY #213: NEW ANIMAL DRUGS AND NEW ANIMAL DRUG COMBINATION PRODUCTS
ADMINISTERED IN OR ON MEDICATED FEED OR DRINKING WATER OF FOOD PRODUCING
ANIMALS: RECOMMENDATIONS FOR DRUG SPONSORS FOR VOLUNTARILY ALIGNING PRODUCT
USE CONDITIONS WITH GFI #209, 2 (2013) [hereinafter GFI #213].
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guidance to sponsors of antimicrobial animal drugs who are inter-
ested in voluntarily revising their conditions for use of products con-
sistent with GFI #209.63
While the FDA has secured initial support from drug companies
to voluntarily cease nonjudicious use, 64 it is yet to be seen whether
substantial reductions in nontherapeutic uses will actually result.
The FDA has asserted that the voluntary approach will be the fast-
est way to achieve the goal of removing nonjudicious antibiotic use,
because "initiating regulatory action would require that the agency
proceed on a product-by-product basis, [which] would likely create
significantly more disruption to the animal health/agriculture in-
dustry, and would require significantly more resources and time to
implement."65
However, actors outside the agency have expressed concerns that
GFI #209 and GFI #213 will not be effective in ultimately control-
ling antibiotic misuse because of the voluntary nature of the strat-
egies.66 Many argue that it is irrational to think that those who
benefit economically from the use of antibiotics would voluntarily
cease use without further legal mandate or enforcement.67 In this
63. Id. at 3. Judicious use principles include preventative strategies ( uch as appropriate
husbandry, hygiene, and immunization), optimization of current pharmacological infor-
mation and principles; limiting antibiotic use to animals who are ill or at risk; minimizing
environmental contamination; and keeping accurate records of treatment and outcome kept
for evaluation. FDA, Judicious Use of Antimicrobials, U.S. DEP'T OF HEALTH AND HUM.
SERV., http://www.fda.gov/AnimalVeterinary/SafetyHealthlAntimicrobialResistance/Judi-
ciousUseofAntimicrobials/. The FDA established a 3-year timeframe for stakeholders to com-
ply with the guidance by voluntarily phasing-in or implementing judicious use principles and
modifying product labels for sponsors of affected products. GFI #213, supra note 62, at 9.
64. FDA, FDA Secures Full Industry Engagement on Antimicrobial Resistance Strategy,
U.S. DEP'T OF HEALTH AND HUM. SERV. (June 30, 2014), http://www.fda.gov/AnimalVeteri-
nary/NewsEvents/CVMUpdates/ucm403285.htm.
65. FDA, FDA's Strategy on Antimicrobial Resistance-Questions and Answers, U.S.
DEP'T OF HEALTH AND HUM. SERV. (June 11, 2015), http://www.fda.gov/AnimalVeteri-
nary/GuidanceComplianceEnforcement/GuidanceforIndustry/ucm216939.htm#question5.
Note that the FDA's argument that the formal withdrawal process would be too expensive
and time-consuming is rather paradoxical, given that the agency itself has delayed starting
the process for thirty-seven years and has spent a substantial amount of money on defending
their discretion to do so. This argument was made by Judge Katzmann in his dissent in
NRDC III, 760 F.3d at 180 (Katzmann, C.J., dissenting).
66. Both GFI #209 and GFI #213 are non-binding and suggest only voluntary compliance
by the drug companies and agricultural producers; neither provides a legal mandate of en-
forcement, and failure to comply with the endorsed judicious use principles does not result
in a penalty for noncompliance. See Cordova & Kar, supra note 26, at 9. Both GFI #209 and
GFI #213 are introduced by the following statement: "This Guidance represents the [FDA's]
current thinking on this topic. It does not create or confer any rights for or on any person
and does not operate to bind FDA or the public." See GFI #209, supra note 5, at 3; GFI #213,
supra note 62, at 3.
67. See Davis & Rutkow, supra note 28, at 348; see also Lydia Zurlaw, Will FDA's Volun-
tary Plan Actually Reduce Antibiotics in Animal Feed?, FOOD SAFETY NEWS (Dec. 12, 2013),
http://www.foodsafetynews.com/2013/12/fda-finalizes-guidance-for-phasing-out-antibiotics-
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regard, it is worth noting that despite the widespread acknowledge-
ment of the impending public health crisis of antibiotic resistance
and various recommendations to reduce nontherapeutic use in ani-
mal production, drug companies have done shockingly little to re-
duce or remove antibiotics from livestock.68 Additionally, scholars
have pointed out that antibiotic use has become a custom in modern
agriculture, stating that "the use of antibiotics is so ingrained in
this country that it will almost certainly be necessary to implement
regulations phasing out the subtherapeutic use of antibiotics in ag-
riculture."69
Finally, while GFI #209 and GFI #213 do encourage drug manu-
facturers to discontinue selling drugs for "growth promotion", they
do not discourage the continuation of "disease prevention."70 By
failing to distinguish between therapeutic and nontherapeutic uses,
the guidance documents leave open the possibility for medically im-
portant drugs to continue being used at subtherapeutic levels under
the label of disease prevention.71 While the products affected by the
plan will be placed under veterinary oversight, there is no explicit
suggestion that veterinarians not prescribe antibiotics for disease
prevention.72
Overall, while the FDA maintains that the voluntary approach it
has instituted will be the best means of reducing the subtherapeutic
use of antibiotics in animal production, it has ultimately done very
little to eliminate unsafe dosing practices.
in-food-animals/#.VuhlvOZ9160. The article quotes University of Texas law Professor and
Center for Progressive Reform scholar Tom McGarity, stating that "[v]oluntary regulations
are merely suggestions .. . The reason that we have regulatory agencies is because the public
cannot rely on promises by industry to do better." Id. Rep. Louise Slaughter said the guid-
ance is "an inadequate response [with] no mechanism for enforcement and no metric for suc-
cess." Id.
68. See Goforth & Goforth, supra note 9, at 46. Rather, in the face of serious threats of
resistance, the amount of antibiotics used nonjudiciously has increased exponentially. Id.
69. Goforth & Goforth, supra note 9, at 70.
70. Greg Cima, Senators Doubt FDA Can Control Antimicrobial Use, J. AM. VETERINARY
MED. AsS'N (Jan. 28, 2015), https://www.avma.org/News/JAVMANews/Pages/150215o.aspx.
The FDA defines disease prevention as "involv[ing] the administration of an antimicrobial
drug to animals, none of which are exhibiting clinical signs of disease, in a situation where
disease is likely to occur if the drug is not administered." Cordova & Kar, supra note 26, at
9 (citing GFJ #209, supra note 5).
71. See generally Cima, supra note 70; see also Zurlaw, supra note 67.
72. See generally GFJ#213, supra note 62.
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IV. JUDICIAL INTERPRETATION: NRDC V. FDA
A. Background and District Court Holding
On May 25, 2011, a group of advocacy organizationS73 filed suit
against the FDA in a federal district court alleging that the FDA
withheld agency action in violation of the FDCA 74 and the Admin-
istrative Procedure Act ("APA"). 75 Plaintiffs' first claim for relief
asserted that FDCA § 360b(e)(1) compelled the FDA to hold the
hearings proposed in the 1977 NOOHs and, if appropriate after the
hearing, to withdraw approval for the antibiotic uses the NOOHs
listed.76 Plaintiffs' second claim stated that under APA § 706(1),
the FDA's failure to issue final responses to the citizen petitions
filed in 1999 and 2005 constituted unreasonably delayed agency ac-
tion under the APA and the FDA's implementing regulations.77 The
second claim became moot when the FDA issued final responses
denying the 1999 and 2005 citizen petitions and formally withdrew
the 1977 NOOHs.7 8 Plaintiffs then filed a supplemental complaint
alleging a third claim for relief, asserting that FDA's denial of the
citizen petitions was "arbitrary, capricious, an abuse of discretion,
or otherwise not in accordance with law," in violation of FDCA
§360b and APA §706(2).79
District Court Judge Theodore H. Katz granted the Plaintiffs' mo-
tion for summary judgment on their first claim for relief and or-
dered the FDA to initiate the § 360b(e)(1) mandatory withdrawal
proceedings.80 The court dismissed the Defendant's argument that
Plaintiffs claim was moot based on the rescission of the 1977
73. Plaintiffs consisted of a group of advocacy organizations, consisting of the Natural
Resources Defense Council, Inc, The Center for Science in the Public Interest, Food Animal
Concerns Trust, Public Citizen, Inc., Union of Concerned Scientists, Inc. NRDC I, 884 F.
Supp. 2d at 130.
74. (1) The Secretary shall, after due notice and opportunity for hearing to the applicant,
issue an order withdrawing approval of an application filed pursuant to subsection (b) of this
section with respect to any new animal drug if the Secretary finds-(A) that experience or
scientific data show that such drug is unsafe for use under the conditions of use upon the
basis of which the application was approved or the condition of use authorized .... 21 U.S.C.
§ 360b(e)(1).
75. "The reviewing court shall-(1) compel agency action unlawfully withheld or unrea-
sonably delayed; and (2) hold unlawful and set aside agency action, findings, and conclusions
found to be-(A) arbitrary, capricious, an abuse of discretion, or otherwise not in accordance
with law." 5 U.S.C. § 706.
76. NRDCI, 884 F. Supp. 2d at 140.
77. NRDC II, 872 F. Supp. 2d at 330.
78. Id.; Withdrawal of Notices of Opportunity for a Hearing; Penicillin and Tetracycline
Used in Animal Food, 76 Fed. Reg. 79,697 (Dec. 22, 2011);
79. NRDC II, 872 F. Supp. 2d at 330. Under FDA regulations, the denial of a citizen
petition is a final agency action subject o judicial review. See 21 C.F.R. § 10.45(d) (2016).
80. NRDCI, 884 F. Supp. 2d at 151.
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NOOHs, stating that formal withdrawal of the 1977 NOOHs did not
rescind the original findings that subtherapeutic use of the drugs
in food producing animals has not been shown to be safe.81 The FDA
was instructed to issue a withdrawal order unless the manufactur-
ers could rebut the finding by proving that the use of the drugs did
not pose a threat to human health.82 The court also granted the
Plaintiffs request for relief under APA §706(2).83 The court found
first that the FDA's denial of the citizen suits was subject to judicial
review, and second, that the FDA's proffered grounds for denying
the petitions-the time and expense required for a formal hearing
and the recent adoption of GFI #209 and #213-were arbitrary and
capricious.84
B. Second Circuit Opinion
On review, the Second Circuit Court of Appeals reversed the opin-
ion of the District Court on both counts.85 Circuit Judge Gerard E.
Lynch, writing for the majority, stated that the text of § 360b(e)(1)
does clearly require the FDA to proceed with withdrawal proceed-
ings for certain uses of antibiotics if the FDA makes a finding that
those uses are not shown to be safe for humans.86 However, the
statute does not clearly specify when such a finding is officially
made.87 Therefore, the issue turns on when a finding becomes for-
malized enough to trigger the mandatory withdrawal process. The
Plaintiffs argued that the mandatory withdrawal process is trig-
gered by an internal agency finding based on scientific evidence.88
The FDA's position, in contrast, was that the mandatory with-
drawal process is triggered only after a finding reached at the end
of a hearing.89
The court agreed with FDA's statutory interpretation that Con-
gress does not require the FDA to hold hearings based on internal
agency deliberations, even when they indicate scientific concerns
81. Id.
82. Id.
83. NRDC II, 872 F. Supp. 2d at 342.
84. Id. at 338-42.
85. NRDC III, 760 F.3d 151, 153 (2d Cir. 2014).
86. Id. at 158.
87. Id. The opinion states, 'The Parties dispute the circumstances under which the man-
datory language 'shall ... issue an order withdrawing approval' comes into play. In particu-
lar, they dispute what it means for the Secretary to make a finding, and when that finding
occurs." Id.




about the safety of animal drug use. Rather, the FDA retains dis-
cretion to institute or terminate proceedings to withdraw approval
of animal drugs, unless a finding that the drug poses a threat to
human health and safety is reached at the conclusion of a hearing. 90
Because internal FDA findings do not meet the requirements of a
formal finding under § 306(b), the court dismissed plaintiffs' first
claim for relief and remanded the issue to the district court to grant
the defendant's motion for summary judgment.91
The majority also dismissed the Plaintiffs' second claim for relief
asserting that the denial of the citizen petition was arbitrary or ca-
pricious agency action in violation of § 706(2)(A) because the denials
were based on factors not mentioned in the statute.92 The court
concluded that the decision of whether to institute or terminate a
hearing process for an animal drug is a discretionary decision left
to the choice of the FDA. Consequently, the court found it "rela-
tively easy" to accept the FDA's justifications denying the Petitions,
including considerations of "cost, time, and a preference for volun-
tary compliance over adversary proceedings ."93
Chief Judge Katzmann issued a dissenting opinion, asserting
that § 360b(e)(1) requires the FDA to continue the proposed with-
drawal proceedings based on the formal declarations of the FDA as
contained in the 1977 NOOHs. Further, he argued that the FDA's
denial of the citizen petitions was arbitrary and capricious because
it relied on outside factors and failed to address the statutory re-
quirement that the drug use is shown to be safe.94
C. Analysis
The Second Circuit erred in two respects: first in holding that a
finding which would mandate the withdrawal process occurs only
after a hearing is held, and second in awarding the FDA discretion
in denying the citizen petitions.
Regarding the first issue, although the text of §360b(e)(1) clearly
requires withdrawal of approval once such a finding has been made,
the statute does not clearly specify exactly what type of finding
mandates the withdrawal process or when that finding occurs.95
While the Court acknowledged that the textual placement of the
90. Id. at 171-72.
91. NRDC III, 760 F.3d at 176.
92. Id. at 173.
93. Id. at 173, 175.
94. Id. at 176-77
95. Id. at 158.
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notice and hearing provision is awkward under either interpreta-
tion, it supported the FDA's interpretation that the finding provi-
sion is structurally linked with the mandatory withdrawal provi-
sion and not linked to the mandatory hearing provision.96 However,
several points support the Plaintiffs' argument that an internal
agency finding is linked to the mandatory hearing provision.
First, consider that an identical congressional design for approval
and withdrawal of drugs exists for non-animal drugs under § 355.97
Both, in identical syntax, indicate that the FDA is required to with-
draw approval for the drug once it provides a hearing and makes a
finding that a particular drug is not shown to be safe.98 The avail-
able evidence indicates that courts have construed § 355 for non-
animal drugs to require the FDA to move forward with withdrawal
proceedings (by holding the necessary hearing) if a preliminary
finding is made that a drug is not shown to be safe.99 Thus, it is
logical that a hearing on the withdrawal of animal drugs would pro-
ceed when a preliminary finding that the drug is not shown to be
safe.
Second, nothing in the FDCA explicitly requires the FDA to "cling
so tenaciously to formal procedures," or to insist that a decision be
made on substantial evidence of the record.100 Section 512(e)(1) of
the FDCA does not contain any particular format for the required
hearing, and does not say the agency's decision must be made on
the record.101  In contrast, another provision of the FDCA,
§701(e)(1), identifies FDA decisions that are to be accompanied by
a public hearing and made on substantial evidence of record at such
96. Id. at 161.
97. NRDC III, 760 F.3d at 180. The minimum due process protections-notice and op-
portunity to be heard-are the same as those for the approval and withdrawal of approval
for non-animal drugs under 21 § 355(c)-(d).
98. Id. at 180-81. For comparison, the first sentence of § 355(e) reads: "The Secretary
shall, after due notice and opportunity for hearing to the applicant, withdraw approval of an
application with respect to any drug under this section if the Secretary finds that [any of the
listed statutory grounds apply]." 21 U.S.C. § 355(e) (2015).
99. NRDC III, 760 F.3d at 180-81. In FDA u. Brown & Williamson Tobacco Corp., 529
U.S. 120 (2000), the precise interpretation of§ 355(e) was not at issue. But the Court's anal-
ysis proceeded under the assumption that once the FDA determines a product under its ju-
risdiction is not show to be safe, it is statutorily required to begin withdrawal proceedings.
See id. at 135; see also Am. Pub. Health Ass'n u. Veneman, 349 F. Supp. 1311, 1315-16 (D.D.C.
1972) (holding that the FDA must commence withdrawal proceedings after announcing in
the Federal Register that certain drugs were not shown to be effective for their approved
uses).
100. Lisa Heinzerling, Undue Process at the FDA: Antibiotics, Animal Feed, and Agency
Intransigence, 37 VT. L. REV. 1007, 1019 (2013). She also highlights that FDA has failed to
recognize the availability of generic rulemaking to address the risks posed by antibiotics in
animal feed as a whole class, rather than on a "drug by drug" basis. Id. at 1019-20.
101. See id. at 1020.
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hearing under § 701(e)(3).102 Yet, of all the regulatory decisions con-
templated by the FDCA, Congress decided not to include the deci-
sions to withdraw approval for animal drugs in the § 701(e)(1) ex-
clusive list of those decisions that require a formal hearing.103 Fur-
ther evidencing this intent, another provision of the FDCA not in-
cluded on the § 701(e)(1) list explicitly imported the requirements
of a formal hearing (expressly stating that § 701(e) applies).1 0 4 In
contrast, section 512(e)(1) does not adopt § 701(e) or its reference to
a full formal evidentiary hearing (or an "evidence of record").105
The third point involves the traditional understanding of an ad-
ministrative "finding." The FDA claimed that a finding typically
represents an official determination or reflects a final, deliberative
decision; is issued at the conclusion of a process; or takes a fixed
form embodied in an identifiable document.106 However, other ar-
eas of the law have defined "findings" to mean written conclusions
based on factual investigations, and other congressional statutes
that refer to only a single finding have been found to imply both a
pre-hearing and post-hearing finding.107 Agency action frequently
begins with a preliminary agency finding that triggers notice and
opportunity for hearing rather than beginning with a hearing.108 As
mentioned by the dissent, "agencies do not arbitrarily decide to ini-
tiate hearings; instead, they begin the hearing process only when
they find there is some reason to do so."109
Finally, mandating action upon a preliminary finding (or one that
is not the result of the required hearing) does not necessarily pre-
sent future problems in terms of identifying when and how such a
102. Id. at 1021. The selective list of § 701(e)(3) thus names specific FDA decisions that
are to be accompanied by a hearing on the evidence of record, which includes, among others,
the labeling of food offered for special dietary uses and tolerance for poisonous ingredients in
food. Id.
103. Id.
104. "The provision on color additives for foods, drugs, and cosmetics expressly states that
section 701(e) applies to the issuance, amendment, or repeal of regulations under that provi-
sion. The provision also expressly adopts the APA's requirements on burdens of proof and
other matters in formal hearings." Heinzerling, supra note 100, at 1022.
105. Id.
106. NRDC III, 760 F.3d at 167. The opinion reads, "Judicial or administrative findings
most commonly are adopted not as a prerequisite but as a consequence of a hearing or other
official proceeding." Id.
107. Id. at 183; see 15 U.S.C. §2603(c)(4)(B); 20 U.S.C. §1099b(1(1); 26 U.S.C. § 7518(e)(2);
and 42 U.S.C. § 6947(a)(2). The procedure often runs "preliminary finding, hearing, final
finding, order," rather than "hearing, finding, order." NRDC III, 760 F.3d at 184 (Katzmann,
C.J., dissenting).




finding has been made.110 The Plaintiffs did not contend that the
withdrawal process should be initiated based on the subjective be-
lief of the FDA; rather, they pointed to the 1977 NOOHs, which set
forth the scientific conclusions of the CVM regarding safety is-
sues.111 Even though the NOOHs were eventually withdrawn, the
agency itself explicitly stated that the withdrawal of the NOOHs
did not withdraw its concerns for the safety of antibiotic use in an-
imal feed, and the FDA repeatedly and consistently reaffirmed the
findings produced in the 1977 NOOHs.112 The court overlooked the
fact that that these were not merely subjective beliefs of the FDA,
but were beliefs that were published in a formal document and re-
peatedly reaffirmed by the agency.
The court also erred in holding that the decision to initiate the
withdrawal process was an enforcement action that is awarded
agency discretion.113 Accordingly, the court deferred to the FDA's
determination that voluntary compliance would offer greater possi-
bilities for reductions in animal antibiotic use than would pursuing
a hearing to determine if the drug is in fact detrimental to human
health.1 14 Unfortunately, the Court overlooked an important excep-
tion to agency discretion in enforcement actions, and further mis-
classified the FDA's decision as an enforcement decision when it
more closely resembles rulemaking action.115
First, while the APA contains a presumption for judicial review,
there is a narrow exception to the presumption; "judicial review is
not available for 'agency action that is committed to agency discre-
tion by law,"' such as when an agency refuses to institute investiga-
tive or enforcement proceedings.116 However, the exception can be
110. Id. at 169. The court stated, "[...] if the NOOHs embody (or contain) the requisite
findings, and revocation of the NOOHs does not suffice to withdraw them, where do the find-
ings exist? In the thoughts and beliefs of the Secretary or Commissioner? Scattered across
various agency documents reflecting such thoughts?" Id. at 170.
111. Id. at 185 (Katzmann, CJ., dissenting).
112. Id. In fact, the FDA has yet to issue a single statement undermining the findings
contained in the 1977 NOOHs.
113. See Id. at 175.
114. . See NRDC III, 760 F.3d at 176. The majority wrote:
It is not for us to determine whether the agency has been prudent or imprudent, wise
or foolish, effective or ineffective in its approach to this problem. Whether the agency's
long inaction in the face of the dangers highlighted in the 1977 NOOH's represented
politically-inspired foot-dragging or wise caution in developing a cost-effective ap-
proach, it was for the agency, and not the courts, to determine how best to proceed.
Id.
115. For a more in depth discussion of the administrative law issues and the standards
governing review of agency action, see Case Comment, Administrative Law-Reviewability-
Second Circuit Upholds FDA's Decision Not to Withdraw Approval from Potentially Danger-
ous Animal Drugs: Nat. Res. Def. Council, Inc., v. FDA, 128 HARV. L. REV. 1011 (2015).
116. NRDC III, 760 F.3d at 186 ((Katzmann, CJ., dissenting) (internal citation omitted).
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rebutted where the statute provides clear guidelines regarding the
exercise of enforcement powers.117 Here, the text of § 360b(1)(e)
places clear limits on agency discretion by requiring the FDA to
commence withdrawal proceedings whenever it finds a particular
drug is not shown to be safe.118
Second, the withdrawal proceedings of § 360b(e)(1)(B) more ap-
propriately fall into the category of rulemaking action than enforce-
ment action.119 Therefore, the review of agency action should be
held to the standard established for rulemaking actions in Massa-
chusetts v. EPA.120 Massachusetts v. EPA forbids an agency from
relying on outside factors when refusing to make a particular stat-
utory determination.121 When the presumption against judicial re-
view is removed, it is easy to determine that the FDA denial of the
citizen petitions was arbitrary and capricious because the reasons
for denying the petitions were "divorced from the statutory text."122
The FDA cannot refuse to make a determination required by stat-
ute because it prefers a different regulatory strategy; it must re-
spond to the citizen petition by addressing whether the drug uses
at issue are shown to be safe. 123
On September 8, 2014, the Plaintiffs petitioned for a rehearing
en banc of the Second Circuit's 2-1 decision, listing two reasons for
rehearing.124 The Plaintiffs' Petition states that the Plaintiffs seek
a rehearing en banc because the case involves questions of excep-
tional importance; the majority's conclusion that the agency is not
required to carry out its statutory mandate "leaves unremedied a
health problem of critical importance."12 5 Second, the Petition as-
117. Id.
118. Id. at 177, 187 (Katzmann, C., dissenting). "The Secretary shall, after due notice
and opportunity for hearing to the applicant, issue an order withdrawing approval of an ap-
plication ... if the Secretary finds-... (B) that new evidence . . . shows that such drug is not
shown to be safe for use. . . ." 21 U.S.C. § 360b(e)(1) (emphasis added).
119. Id. at 188-89 (Katzmann, C.J., dissenting).
120. 549 U.S. 497 (2007). See NRDC III, 760 F.3d at 188 (Katzmann, C.J., dissenting)
(asserting the Massachusetts holding). See generally Massachusetts, 549 U.S. 497 (2007)
(holding that the statute allowed the administrator initial discretion, but that once an en-
dangerment finding was made, action became mandatory and could not be justified by rea-
sons divorced from the statute.)
121. See NRDC III, 760 F.3d at 188 (Katzmann, C.d., dissenting).
122. Massachusetts, 549 U.S. at 531-34 (reasons for action or inaction must be grounded
in the statute).
123. See NRDC III, 760 F.3d at 192-93 (Katzmann, C.d., dissenting).
124. NRDC III, 760 F.3d 151 (2d Cir. 2014), petition for rehearing en bane filed, (Septem-




serts that the majority decision conflicted with Supreme Court de-
cisions in Massachusetts and Chevron.126 As of this writing, the Sec-
ond Circuit has yet to grant rehearing.
V. THE LEGISLATIVE AND EXECUTIVE RESPONSE
A. Proposed Legislation
Based on the FDA's failure to address concerns over growing an-
tibiotic resistance and armed with a growing body of scientific evi-
dence, over 300 organizations and groups have expressed support
for legislation that would phase out non-therapeutic use of antibi-
otics in farm animals and ban antibiotics vital to human health.127
Accordingly, there have been numerous attempts to introduce re-
form legislation by both houses of Congress. For example, Repre-
sentative Louise Slaughter (D-NY) has introduced versions of H.R.
1150-The Preservation of Antibiotics for Medical Treatment Act of
2013 (PAMTA) 128-to Congress in 2003, 2005, 2007, 2009, and
2013.129 Senator Dianne Feinstein (D-CA) introduced a similar bill
in 2013 titled Senate Bill 1256-Preventing Antibiotic Resistance
Act of 2013 (PARA).130
PAMTA and PARA have several similar provisions designed to
preserve the use of medically important antibiotics. These provi-
sions specify the need to: (1) amend the FDCA so that drug manu-
facturers have the initial burden of proof of safety of the nonthera-
peutic antibiotic use; (2) reduce and eventually eliminate the non-
therapeutic use of antibiotics in animal feed and water; (3) prohibit
antibiotic use for animals that are not diseased; (4) prohibit the
practice of routine antibiotic use for disease prevention, and (5) en-
sure that veterinarians administering antibiotics have a connection
126. Id.; See also Andrew Westney, NRDC Urges 2nd Circ. To Rehear Livestock Antibiotic
Suit, LAW 360 (Sept. 10, 2014), http://www.1aw360.com/articles/575628?utmsource
=rss&utm medium=rss&utmcampaign= articles search.
127. Preservation of Antibiotics for Medical Treatment Act: Hearing on H.R. 1549 Before
the HR Committee on Rules, 111th Cong., 4 (2009) (statement of Robert P. Martin, Senior
Officer, The Pew Environment Group).
128. Preservation of Antibiotics for Medical Treatment Act of 2013, H.R. 1150, 113th
Cong. (2013).
129. See H.R. 1549, 111th Cong. (2009); H.R. 962, 110th Cong. (2007); H.R. 742, 109th
Cong. (2005); H.R. 2932, 108th Cong. (2003).
130. Preventing Antibiotic Resistance Act of 2013, S. 1256, 113th Cong. (2013). Addition-
ally, the Strategies to Address Antimicrobial Resistance Act, H.R. 2400, 111th Cong. (2009),
was introduced to Congress in 2007 and 2009. See Davis & Rutkow, supra note 28, at 358.
The Strategies to Address Antimicrobial Resistance (STAAR) Act would amend the Public
Health Service Act to create an Office Antimicrobial Resistance modeled after the Task Force
established in 1999. Id.
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with the animals they are prescribing to.1 3 1 PAMTA, for example,
defines nontherapeutic use as, "[the] administration of antibiotics
to an animal through feed or water [...] for purposes (such as growth
promotion, feed efficiency, weight gain, or disease prevention) other
than therapeutic use or nonroutine disease control."132
Additionally, Representative Henry Waxman (D-CA) introduced
H.R. 820-The Delivering Antimicrobial Transparency in Animals
Act-in 2013.133 H.R. 820 enhances the reporting requirements per-
taining to antimicrobial drug use in food animals. It would require
all major industrial farmers to submit detailed reports to the FDA
regarding the type and amount of antibiotics used in animal feed. 134
B. The Executive Response - PCAST Report, Executive Order and
National Strategy
The Obama Administration has stated that it considers the de-
velopment and spread of antibiotic resistance to be a "top national
security and public health priority." 135 To address the issue, on Sep-
tember 18, 2014, the Obama Administration released a set of fed-
eral actions to combat the rise of antibiotic-resistant bacteria, in-
cluding an Executive Order 36 and A National Strategy for Combat-
ing Antibiotic-Resistant Bacteria ("CARB Strategy").137 Both ac-
tions were based on a new report from the President's Council of
Advisors on Science and Technology ("PCAST") entitled Combating
Antibiotic-Resistant Bacteria ("PCAST Report").138
131. Brian Krans, Politics Stall Antibiotics Ban in Congress, HEALTHLINE (July 24, 2014),
http://www.healthline.com/health/antibiotics/politics-pork-and-poultry-why-legislation-has-
not-passed. For example, the current PAMTA bill proposes to amend Sections 201 and 512
of the FDCA to withdraw approval for certain critically important antimicrobials for non-
therapeutic use, thus requiring the FDA to eliminate the nontherapetic use of eight classes
of antimicrobials in food producing animals within two years.
132. Preservation of Antibiotics for Medical Treatment Act of 2013, supra note 128, at
4(a).
133. Delivering Antimicrobial Transparency in Animals Act of 2013, H.R. 820, 113th
Cong. (2013).
134. Id.
135. Press Release, The White House Office of Communications, Fact Sheet: Obama Ad-
ministration Takes Actions to Combat Antibiotic-Resistant Bacteria, (Sept. 18, 2014),
https://www.whitehouse.gov/the-press-office/2014/09/18/fact-sheet-obama-administration-
takes-actions-combat-antibiotic-resistan [hereinafter White House Press Release].
136. Exec. Order No. 13676184, 184 Fed. Reg. 56,931 (2014).
137. THE WHITE HOUSE, NAT'L STRATEGY FOR COMBATING ANTIBIOTIC-RESISTANT
BACTERIA (Sept. 2014) [hereinafter CARB STRATEGY]. The actions also included the launch
of a twenty-million-dollar prize to "facilitate the development of rapid, point-of-care diagnos-
tic tests for health care providers to identify highly resistant bacterial infections." White
House Press Release, supra note 135.
138. PCAST REPORT, supra note 1. The Report was publicly released along with the Ex-
ecutive Order and National Strategy on September 18, 2014. See Id.
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The PCAST Report recommendations for action occur in three fo-
cused areas: improving the surveillance and research of antibiotic-
resistant bacteria, improving appropriate use of existing antibiotics
to increase longevity, and developing and discovering new antibiot-
ics and alternatives.1 39 Despite the fact that the Report devoted
little space to antibiotics in animal agriculture, it noted that "the
risks to human health posed by the agricultural use of antibiotics
are . . . a matter of very serious concern."14 0 Recommendations in-
cluded development of more research through additional funding
and strong support of the "FDA's new Guidances 209 and 213, de-
signed to promote the judicious use of antibiotics in agriculture."1 4 1
PCAST concluded that the FDA should monitor the sales of medi-
cally important antibiotics and collect data, concluding that, "[i]f
the FDA guidances are not effective in mitigating the risk of anti-
biotic resistance associated with antibiotic use in animal agricul-
ture, [the] FDA should take additional measures."1 4 2
The Executive Order initially established the Presidential Advi-
sory Council on Combating Antibiotic-Resistant Bacteria to provide
advice, information, and recommendations to the Secretary on com-
bating antibiotic resistance.143 It then directed the federal govern-
ment to implement the national strategy and address the PCAST
Report in order to address antibiotic resistance threats.144 It estab-
lished a new interagency Task Force for Combating Antibiotic-Re-
sistant Bacteria with the mission of identifying actions to imple-
ment and monitor the Executive Order and the National Strat-
egy.1 4 5 The Task Force was given one year to submit a five-year
National Action Plan to the President outlining goals, metrics, and
timelines for implementation.1 4 6 In regards to antibiotic use in food
animals, Section 5(e), generally titled Improved Antibiotic Steward-
ship, instructs the FDA to "continue taking steps to eliminate the
use of medically important classes of antibiotics for growth promo-
tion purposes in food-producing animals."147  Additionally, the
USDA, EPA, and FDA should coordinate on research, findings, and
139. Id. at 2-7.
140. Id. at 2.
141. Id. at 7.
142. Id. at 7. PCAST acknowledged while all 26 animal-drug companies affected by Guid-
ance #213 have agreed to comply with the voluntary changes, "it will be important to see how
the voluntary changes actually impact antibiotic use and stewardship in agriculture." Id. at
53-55.
143. 3 C.F.R. 13676 § 4(c).
144. Id. § 1-2.
145. Id. § 3(b).
146. Id. § 3(c)(i).
147. Id. § 5(e).
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surveillance of antibiotic use and resistance patterns in food-pro-
ducing animals.148
The National Strategy provides actions for five goals related to
combatting antibiotic resistance that are to be achieved by 2020.149
The goals include:
1. Slow the emergence of resistant bacteria and prevent the
spread of resistant infections;
2. Strengthen national One-Health surveillance efforts to
combat resistance;
3. Advance development and use of rapid and innovative di-
agnostic tests for identification and characterization of re-
sistant bacteria;
4. Accelerate basic and applied research and development
for new antibiotics, other therapeutics, and vaccines; and
5. Improve international collaboration and capacities for an-
tibiotic-resistance prevention, surveillance, control, and antibi-
otic research and development. 150
Pertaining to antibiotic use in food animals, Goal 1, Objective 1.2
recommends the elimination of use of medically important antibiot-
ics for growth promotion in animals, and bringing other in-feed uses
of antibiotics under veterinary oversight in line with GFI #213.151
Goal 4 has certain objectives that indicate the need for research on
the relationship between antibiotic use in livestock and the devel-
opment of antibiotic resistance, as well as research into resistance
and its spread among zoonotic pathogens.15 2
148. 3 C.F.R. 13676, § 5(f). Section 6 includes further requirements for Strengthening
National Surveillance Efforts For Resistant Bacteria. "USDA, EPA, and FDA shall work
together with stakeholders to monitor and report on changes in antibiotic use in agriculture
and their impact on the environment." Id. § 6(c).
149. CARB STRATEGY, supra note 137, at 5.
150. Id.
151. Id. at 8. Other in-feed uses include treatment and disease control and prevention of
disease. Id.
152. Id. at 17-19.
560 Vol. 54
Eliminating Antibiotic Use
C. Reception and Analysis
The proposed bills have been met with strong opposition, and
none of them have even neared the floor for debate.153 Key stake-
holders such as agricultural and pharmaceutical companies have
spent a great deal of time and money lobbying against the legisla-
tion.154 These stakeholders argue that the proposed legislation is
flawed for three reasons. First, they claim that the proposed bills
too narrowly define therapeutic use by failing to include the "pre-
vention of disease" in the definition of therapeutic uses; therefore,
the legislation is not aligned with the FDA's recommendations un-
der GFI #209.155 Second, opponents claim there is a need for further
research and planning regarding the degree of connection between
antibiotic use in food animals and antibiotic resistance in humans
before binding regulations are implemented.156
Regarding the Executive action, both the drug and animal pro-
duction industries and the FDA have praised the recent actions
taken by the Obama Administration.15 7 In contrast, critics had
hoped President Obama would go further in regards to antibiotics
used in food animals, and believe the "PCAST recommendations fall
153. See Krans, supra note 131. Krans notes that-according to GovTrack-PAMTA has
a one percent chance of ever being enacted, and PARA has a zero percent chance. Id.
154. For example, lobbing efforts have come from the National Beef Packing Company;
the National Pork Producers Council; The Animal Health Institute; the Food Marketing In-
stitute; Merck & Co., Eli Lilly & Co.; and Pfizer. Id. The economic incentives make opposi-
tion inevitable. For example, the National Research Council estimated that the animal
health industry produced $3.3 billion for pharmaceutical companies in 1995 alone. Davis &
Rutkow, supra note 28, at 362.
155. AMERICAN VETERINARY MED. ASS'N, AVMA ISSUE BRIEF: PRESERVATION OF
ANTIBIOTICS FOR MEDICAL TREATMENT ACT-H.R. 1150 (2014), https://www.avma.org/Advo-
cacy/National/Documents/IB PAMTA_4-1-2014.pdf, [hereinafter AVMA ISSUE BRIEF]; see
GFI #209, supra note 5, at 4.
156. Halpern, supra note 16, at 419. "The correlation between [the two] must be more
extensively explored before a definitive cause and effect can be established." Id. The concern
in this regard is that further harm to human health could result if antibiotics were entirely
prohibited from use in food animals since alternatives have not been extensively explored.
Id. See also AVMA ISSUE BRIEF, supra note 155, at 2.
157. Nat'l Pork Producers Council, American Meat Institute, Groups Respond to White
House Executive Order on Antibiotic Resistance (Sept. 18, 2014), http://nationalhog-
farmer.com/health/groups-respond-white-house-executive-order-antibiotic-resistance; Mar-
garet A. Hamburg, FDA's Take on the Executive Order and National Strategy to Combat An-
tibiotic-Resistant Bacteria, FDA VOICE (Sept. 18, 2014), http://blogs.fda.gov/fdavoice/in-
dex.php/2014/09/fdas-take-on-the-executive-order-and-national-strategy-to-combat-antibi-
otic-resistant-bacteria/. The FDA Voice Blog is available at http://blogs.fda.gov/fdavoice/in-
dex.php.
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short in addressing the critical need to reduce antibiotic use, espe-
cially in livestock."15 8 They point out that while the executive ac-
tions generally endorse better antibiotic stewardship in agriculture,
they do not require that regulatory or legislative action be taken.159
Thus, FDA retains the ultimate discretion to refuse to withdraw the
approval of certain animal drugs, and drug producers and consum-
ers' compliance with judicious use principles remains entirely vol-
untary. The critics also point out that the Executive's primary rec-
ommendation regarding antibiotics used in agriculture authorized
more expensive and time-consuming research on the correlation be-
tween antibiotic use in animals and human health.160 Finally, they
are displeased that the Executive actions include disease preven-
tion in the description of permitted uses.161
In attacking the critiques of the proposed bills and simultane-
ously supporting critics of the Executive action, the following points
are worth making. First, including disease prevention in the defi-
nition of therapeutic uses may permit drug producers to re-label
antibiotics intended for growth promotion as antibiotics for disease
prevention.162 If this re-labeling is done, it would undermine any
efforts to reduce overall antibiotic use.
158. Press Release, Health Care Without Harm and Healthy Food Action, White House
Report on Antibiotic Resistance Disappoints (Sept. 18, 2014), http://www.mar-
ketwatch.com/story/white-house-report-on-antibiotic-resistance-disappoints-2014-09-18.
David Wallinga, MD, Director of Healthy Food Action, stated, "For the White House to punt
leadership on this critical medical and national security issue to the FDA [is] a tragic mis-
take. . . . For four decades, the FDA has failed to take action to reduce antibiotics used in
livestock feed." Id.
159. See Exec. Order No. 13676184 § 10, 184 Fed. Reg. 56,931 § 10 (2014). The relevant
part of the Executive Order § 10 reads:
Nothing in this order shall be construed to impair or otherwise affect ... the authority
granted by law to an executive department or agency . . . This order is not intended
to, and does not, create any right or benefit, substantive or procedural, enforceable at
law or in equity by any party against the United States, its departments, agencies, or
entities, its officers, employees, or agents, or any other person.
Id. at § 10(b)(i), 10(c).
160. PCAST REPORT, supra note 1, at 5. For example, the PCAST report recommends
that a USDA multidisciplinary Innovation Institute be employed to develop alternatives to
antibiotics in agriculture; PCAST projects that the Institute will require $25 in annual fund-
ing. Id.
161. See, e.g., Mae Wu, Breaking Down the President's Plan on Combating Antibiotic Re-
sistance, NRDC (Sept. 18, 2014), https://www.nrdc.org/experts/mae-wulbreaking-down-pres-
idents-plan-combating-antibiotic-resistance; Lisa Schnirring, White House Releases plan to
curb antibiotic resistance, CENTER FOR INFECTIONS DISEASE RESEARCH AND POLICY,
http://www.cidrap.umn.edulnews-perspective/2015/03/white-house-releases-plan-curb-anti-
biotic-resistance.
162. The PCAST Report briefly addressed concerns that antibiotic use intended for growth
promotion could be redesignated as intended for disease prevention, stating that the practice
would be "unethical and illegal." PCAST REPORT, supra note 1, at 54. Unfortunately, this
would likely be hard to monitor with a degree of certainty, and enforcement would remain
another issue entirely.
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Second, demands for more, optimal, or consistent data are only a
means of stalling the implementation of binding regulations. As a
starting point, the tracking of bacterial resistance is markedly dif-
ficult; for example, in the U.S., the current surveillance systems to
collect data from both human and animal populations have been
described as "remain[ing] suboptimal and yield[ing] inconsistent re-
sults."16 3 Further, the drastic consequences of eliminating antibi-
otic effectiveness combined with the speed at which resistance is
developing should outweigh the need for a precise measurement re-
garding a degree of harm caused to humans from animal antibiotic
use.164 The current scientific consensus has established that anti-
biotic use in animals results in adverse consequences for human
health;165 the reality is that harm, to whatever degree, will result
from continued use. Instead, economic expenditures and research
time should be focused on educating animal producers, veterinari-
ans, and the like on alternatives to antibiotics, and any further re-
sources should be devoted to the study of antibiotic resistance in
humans.
Finally, as an additional note regarding further research, oppo-
nents of binding regulatory or legislative action have advocated for
the consideration of risk factors that go beyond the appropriate pa-
rameters of a public health risk assessment.166 These opponents
claim that the harm resulting from eliminating antibiotic use-the
loss of the economic and animal health benefits that the drugs pro-
vide-would outweigh the benefit to human health.1 67  However,
only the human safety of the drug may be considered. As is con-
163. Halpern, supra note 16, at 432. For example, the FDA, CDC, and USDA have six
ongoing surveillance activities pertaining to resistant bacteria, each monitoring different
bacterial varieties and using different laboratory testing methods. Id.
164. This argument is possible because the US requires a risk assessment. In contrast,
the European Union rejected the need for such precise measurements and instead relied on
the precautionary principle to avoid delay in banning five antibiotics in 1998; "[N]o [risk
assessment] predicting human (or animal) health consequences was considered necessary."
Halpern, supra note 16, at 430 (alteration in original). The European Union decided that the
risk of future antibiotic resistance outweighed the risk of increased animal production costs.
Centner, supra note 25, at 30. The precautionary principle states that when the health of
humans is in danger, it may not be necessary to wait for scientific certainty to take remedial
or protective action. David Kriebel, et. al., ,The Precautionary Principle in Environmental
Science, 109 ENVT'L HEALTH PERSP. 871 (2001).
165. Indeed, the task forces that have come to this conclusion have not demonstrated suc-
cess in blunting the overuse of antibiotics. Grover, supra note 57. See, e.g., ITFAR REPORT,
supra note 2.
166. This analysis includes risk factors such as increased rates of mortality and infectious
disease among animals, and decreased animal production. Halpern, supra note 16, at 416-
17.
167. Halpern, supra note 16, at 435.
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tained in the Final Decision of the Commissioner to withdraw ap-
proval for Baytril@, "FDA is not authorized, under the FDCA, to
weigh economic, health or other benefits that the drug provides
against a health risk to the ultimate human consumers of food from
or contaminated by treated animals."168 While the opponents have
attempted to reclassify the detriments to animal health as human
safety considerations, their argument can be dismissed when one
considers that antibiotics are not the only method of maintaining
healthy food animals to ensure safe food for human consumption.1 6 9
Case studies from outside of the U.S. have demonstrated that anti-
biotic bans have been successfully accomplished, allowing only brief
increases in animal mortality and disease, when antibiotic alterna-
tives are effectively implemented.170
VI. CONCLUSION
D. Moving Forward, Possibilities for Reform-Leading Examples
Over the past decades, various countries in the European Union
have taken regulatory action to ban the use of antibiotics as growth
promoters in food animals.171 When faced with the same scientific
data available to the U.S., the EU concern prompted enactment of
a legislative ban on nonessential, or nontherapeutic, antibiotic use
168. FDA, Final Decision of the Commissioner, Withdrawal of Approval of the New Ani-
mal Drug Application for Enrofloxacin in Poultry, 70 Fed. Reg. 44105-01, at 120. In regards
to enrofloxacin, the Commissioner stated, "[e]ven if I were to attempt to weight the benefits
of enrofloxacin against its risks, the record before me is not sufficient to show that the alleged
benefits outweigh the risks." Id.
169. Alternatives typically involve improved production practices such as ensuring better
ventilation, more space per animal, and better hygiene and sanitation standards. C.f. Les-
sing, supra note 21, at 468 (explaining that antibiotics are used to combat infections that
only arose as a result of poor living conditions).
170. Davis & Rutkow, supra note 28, at 361; In some cases, reduced antibiotic dosing and
improved hygienic practices resulted not only in lower mortality rates but actually increased
the value of the production. Increased value will typically be generated because of the con-
sumer demand for antibiotic free meat. For example, McDonald's one of the largest meat
purchasers in the world, only accepts chicken raised without medically-important antibiotics
used for non-therapeutic purposes, and preferences other meat suppliers who comply with
this policy. Other companies have banned all use of non-therapeutic antibiotics in the poul-
try they purchase. Vanessa K.S. Briceflo, Note, Superbug Me: The FDA's Role in the Fight
Against Antibiotic Resistance, 9 N.Y.U. J. LEGIS. & PUB. POL'Y 521, 527-28 (2005-06). More-
over, the costs of improved sanitation and living conditions used to combat increased mortal-
ity can likely be offset by the decrease in the cost of antibiotics. Lessing, supra note 21, at
478. Therefore, the negative human health consequences that may arise from a decline in
animal health can be mitigated by spending to improve farming production practices.
171. Cogliani et. al., supra note 7, at 274. The first ban on antibiotic growth promoters
was enacted in Sweden in 1986, followed by Denmark, The United Kingdom, and The Neth-
erlands. Id.
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in food animals in an attempt to reduce pools of resistant genes.172
Importantly, "the full arsenal of antibiotics remains available to
veterinarians to treat sick animals and herds."1 7 3 Using Denmark
as the primary example, the bans do not limit all antibiotic use.
Rather, they limit antibiotic use by requiring a veterinarian pre-
scription, and mandating that certain drugs found to be particu-
larly important for human medicine only be administered by injec-
tion instead of through feed additives.174
On January 1, 2000, Denmark, one of the world's major pork pro-
viders, banned the use of non-therapeutic antibiotics at all stages
of pork production.175 The "Danish experience" standing alone
should raise serious skepticism regarding industry claims that effi-
cient animal production without antibiotics could not be
achieved.1 76 The reports monitoring the ban have revealed at least
four positive and inspiring conclusions. First, the ban was success-
ful in reducing the amount of antibiotics consumed by food animals;
the total antibiotic usage per pound of pork decreased by greater
than 50 percent.1 7 7 While antibiotic use gradually increased for a
period of time due to the emergence and spread of new diseases,
levels quickly returned to pre-ban levels.178 The reduction of anti-
microbial use has also led to reductions in the average duration of
exposure of animals to antimicrobials.17 9
Second, Denmark's antibiotic ban has had minimal, if any, nega-
tive impact on the nation's pork industry. While antibiotic use per
kilogram of pig raised decreased, overall productivity increased
from 18.4 million weaned pigs in 1992, to 27.1 million in 2008 (a 43
172. Id. at 274-75.
173. Kathy Talkington, What Can Danish Hogs Teach Us About Antibiotics?, THE PEW
CHARITABLE TRUSTS (Oct. 13, 2009), http://www.pewtrusts.org/en/about/news-room/opin-
ion/2009/10/13/what-can-danish-hogs-teach-us-about-antibiotics.
174. Preservation of Antibiotics for Medical Treatment Act of 2009: Hearing on H.R. 1549
Before the HR Committee on Rules, 111th Cong. 1, at 1-2 (2009) (statement of Dr. Frank
Moller Aerestrup and Dr. Henrik Wegener, National Food Institute, Technical University of
Denmark) [hereinafter Moller & Wegener Statement].
175. Id. Prior to the mandatory ban, the Danish government instituted a voluntary ban
on the non-therapeutic use of antimicrobials at the finishing stage of production, adding a
$2.00 tax per pig for noncompliance. Id. at 2.
176. Id.
177. Id. at 2. Use in Denmark reached only 47 mg/kg during the peak of use, whereas the
U.S. uses 250-300 mg/kg. Id.
178. THE PEW CHARITABLE TRUSTS,, AVOIDING ANTIBIOTIC RESISTANCE, DENMARK'S BAN
ON GROWTH PROMOTING ANTIBIOTICS IN FOOD ANIMALS (Nov. 1, 2010),
http://www.pewtrusts.org/-/mediallegacy/uploadedfiles/phg/contentlevel pages/is-
suebriefs/denmarkexperiencepdf.pdf.
179. WORLD HEALTH ORGANIZATION, IMPACTS OF ANTIMICROBIAL GROWTH PROMOTER
TERMINATION IN DENMARK, 6 (Nov. 2002) [hereinafter WHO REPORT].
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percent increase in production).1 80 The average number of pigs pro-
duced per sow increased by four, which is a positive indicator of
swine health and welfare.18 1 To be sure, pig mortality increased for
a short period immediately following the withdrawal of antibiotics,
creating a short-term need to increase therapeutic antibiotic use.
However mortality rates fell sharply as of 2004, and as of 2008, they
have returned to pre-antibiotic ban levels.182 Danish scientists
claim that, overall, swine productivity has increased even as anti-
microbial use has decreased.183
Third, data from Denmark has shown a marked decline in the
prevalence of antibiotic resistant bacteria in both food animals and
healthy humans.184 In some cases, the levels of a particular re-
sistant bacteria declined only two years after the cessation of a par-
ticular antibiotic.185 Extensive data has shown that the termination
of antimicrobial growth promoters has fundamentally reduced the
food animal reservoir of antibiotic resistant bacteria, and therefore
reduced a reservoir of resistant genes that can transfer to several
clinically important antibiotics for humans.186
Fourth, the cost of raising pigs has not drastically risen despite
critics' claims that the removal of antibiotics cannot be done cost
effectively. According to a veterinarian with the Danish Agricul-
tural and Food Council, "the cost of raising pigs has gone up by
about C1 per animal, from birth to slaughter, since the ban."187 The
2003 WHO report also found that overall economic impacts were
minimal, translating to a production cost increase of just over one
percent in swine and a zero percent increase in poultry.1 88 This has
been accomplished through more efficient production and hus-
bandry practices that lead to less disease.189
180. Sharon Levy, Reduced Antibiotic Use in Livestock: How Denmark Tackled Resistance,
122 ENVTL HEALTH PERSP. A160, A162 (2014).
181. Moller & Wegener Statement, supra note 175, at 2.
182. Levy, supra note 180, at A162. But see Mark Casewell, et al., The European Ban on
Growth-Promoting Antibiotics and Emerging Consequences for Human and Animal Health,
52 J. OF ANTIMICROBIAL CHEMOTHERAPY 159, 161 (2003) (highlighting some of the adverse
consequences to a widespread ban of antibiotics as growth promoters that occurred in years
immediately following the ban).
183. Moller & Wegener Statement, supra note 175, at 2.
184. Levy, supra note 180, at A162.
185. Id.
186. WHO REPORT, supra note 179, at 6. However, further studies are needed to deter-
mine the effect the discontinued use of antibiotics in animal agriculture will have on antibi-
otic resistance in humans. Id.
187. Levy, supra note 180, at A162.
188. THE PEW CHARITABLE TRUSTS, supra note 178, at 3.
189. Id. at 2. Some of the methods included altering production systems by adopting other
feed ingredients, tightening biosecurity, increasing weaning weight, improving sanitation,
reducing density, and more. Id. at 5. Another of these methods includes allowing piglets to
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Additionally, some U.S. research has already indicated that the
costs of production are reduced when antibiotics are not used when
considering the increased cost of feed containing antibiotics.190 And
importantly, the cost-benefit analysis swings even more in favor of
alternatives to subtherapeutic uses when accounting for societal
and environmental costs of antibiotic use. For example, the fact
that antibiotic-resistant diseases are more prevalent in rural farm-
ing communities creates social equity concerns,191 and runoff from
the land application of manure containing antibiotics can pollute
streams and kill living organisms.192 When accounting for societal
and environmental harm, industrial swine farming methods are un-
questionably more expensive than alternative methods which do
not use antibiotics for growth promotion.193
Unfortunately, despite the fact that the research collected from
the Danish Integrated Antimicrobial Resistance Monitoring and
Research Program (DANMAP), shows that the Danish ban has re-
duced human health risk without significantly harming animal
health or farmers' incomes, representatives of organizations funded
by industry forces have often criticized and misrepresented facts
emerging from the Danish study.194 Thus, the Danish success in
using alternatives is often overlooked in the U.S. However, the ev-
idence from Denmark and other countries across Europe has been
convincing enough to inspire the entire European Union to ban the
use of antibiotics as growth promoters in 2006.195 Hopefully, as a
trend emerges, the data will be harder to manipulate.
stay with their mothers for longer periods of time after birth, allowing them to naturally
build their immune systems; Piglets that are separated from their mothers at early ages have
been found to be more susceptible to infection. Levy, supra note 179, at A162.
190. THE PEW CHARITABLE TRUSTS, supra note 178, at 3-4. Researchers from John Hop-
kins University have found that the increased cost of feed containing antibiotics outweighs
the costs associated with the increased amount of feed needed, plus slightly increased mor-
tality, variability in weight gain, and increased condemnation rates (chickens with illness or
disease). Id.
191. PCAST REPORT, supra note 1, at 51.
192. See Hannah M.M. Connor, The Industrialization of Animal Agriculture: Connecting
a Model With Its Impacts on the Environment, in FOOD, AGRICULTURE, AND ENVIRONMENTAL
LAW 65, 69 (Mary Jane Angelo, Jason J. Czarnezki, and William S. Eubanks II eds.) (2013).
The USDA has estimated that confinement operations produce around 500 million tons of
manure annually. Id. (citing U.S. EPA, National Pollution Discharge Elimination System
Permit Regulations and Effluent Limitation Guidelines and Standards for Concentrated An-
imal Feeding Operations; Final Rule, 68 Fed. Reg. 7176, 7180 (Feb. 12, 2003)).
193. See THE PEW CHARITABLE TRUSTS, supra note 178, at 3.
194. Moller & Wegener Statement, supra note 175, at 1.
195. Levy, supra note 180, at A162-63.
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E. Recommendations and Conclusion
First, the U.S. must continue to strengthen and improve NARMS
surveillance systems to trace pathogens,196 as well as establishing
a surveillance system to monitor antibiotic sales and use.197 Sec-
ond, Congress must pass legislation that will initiate the process of
withdrawal of approval of drugs that are considered medically im-
portant in human medicine in order to put the burden of proving
the safety of the drug on the manufacturer.198 Importantly, the leg-
islation must properly distinguish between therapeutic and non-
therapeutic use, the latter including both disease prevention and
growth promotion, and provide clear language to eliminate the pos-
sibility of relabeling.199 Third, information and advice on alterna-
tives to antibiotic use must be collected and disseminated to help
producers who are accustomed to the use of routine antibiotics.200
Federal and/or state grants to aid farmers in the transition into to-
tal elimination of subtherapeutic antibiotic use could also be of
great importance.201 Fourth, along with information to aid in com-
pliance, the U.S. must create a system of monitoring and enforce-
ment that mandates antibiotic reduction and imposes fines for non-
compliance.202 Finally, the U.S. must continue to work with other
196. NARMS is still working to establish universally acceptable, science-based testing
methods, critical pathogen indicators, and surveillance tools to provide uniform data for anal-
ysis. Halpern, supra note 16, at 432-33.
197. Close monitoring of antibiotics sales and use has been an essential part of the Danish
system to establish baseline data, to track the amount of antibiotics used in both animals
and humans, and to monitor resistance in pathogens and indicator organisms. Levy, supra
note 180, at A162 and A163. The DANMAP information system established in Denmark
includes extensive monitoring systems that track drug resistance and antimicrobial use and
services for research and ata analysis. The information also served to identify farmers who
continued to overuse antibiotics, and was used to convince the agricultural community that
the ban had a positive effect on public health. Id.
198. For example, proposed legislation like PAMPTA and PARA propose to withdraw the
use of 7 classes of antibiotics vitally important to human health from sub therapeutic use in
food animal production. Krans, supra note 131.
199. See Levy, supra note 180, at A164.
200. To implement the Swedish ban, large efforts were dedicated to problem-solving and
to providing services to farmers; Officials developed guidelines on appropriate feed, medicat-
ing, management, and hygiene practices to keep animals healthy and to prevent infection.
Cogliani et al., supra note 7, at 276-77.
201. See Orrico, supra note 31, at 284.
202. For example, when the Dutch promulgated regulations to limit antibiotic use in ani-
mals without a plan to implement or enforce, antibiotics were still used extensively due to
insufficient government control over antibiotic use and sales. The Netherlands have since
imposed a mandate to reduce antibiotics in animals by 50% in the next three years, estab-
lished a registration process for veterinary prescriptions, and have begun to impose fines for
noncompliance. Cogliani et al., supra note 7, at 275-76.
Eliminating Antibiotic Use
countries to create international standards that restrict certain ag-
ricultural uses of antibiotics.203
The scientific community and organizations around the world
have reached the consensus that antibiotic use in animals is dan-
gerous to the public health, and there has already been success us-
ing alternatives to antibiotics to maintain animal health and pro-
duction. Yet despite growing concerns, the agency charged with
protecting the safety of the food supply has refused to enact binding
regulations to fix the problem. Action must be taken immediately
to reverse this trend. The U.S. should forgo any further delay or
expenditures of time in the pure research stage and should begin
implementing the withdrawal of non-therapeutic antibiotic use in
animal production. In line with the recommendations above, gov-
ernment spending should be focused on helping farmers implement
the bans and on disseminating and tracking information about an-
tibiotic resistance generally. Any additional funds can be better di-
rected toward preserving antibiotic effectiveness in human medi-
cine. The bottom line is that antibiotics are a limited resource and
must be conserved to help preserve their life-saving potential for
the future; the more used today, the less availability and effective-
ness in the future.204
203. Others have recommended the need for international standards. See, e.g., PCAST
REPORT, supra note 1, at 56. Recommendation 8 of the PCAST Report recommends that the
federal government:
[V]igorously support development of the WHO Global Action Plan and continue to el-
evate the issue of antibiotic resistance to the level of a global priority by encouraging
or requiring, as appropriate, coordination among countries for surveillance, reporting,
research, antibiotic stewardship, and development of new and next-generation drug
and diagnostics equipment.
Id. at 57.
204. CDC REPORT, supra note 2, at 41.
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